Fiduciary/Claymore Infrastructure Fund EBITDA margin
Mi az Fiduciary/Claymore Infrastructure Fund EBITDA margin?
A EBITDA margin az Fiduciary/Claymore Energy Infrastructure Fund - -466.20%
Mi a EBITDA margin meghatározása?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin a Finance szektor a NYSE-on cégekben a Fiduciary/Claymore Infrastructure Fund -hoz képest
Mit csinál Fiduciary/Claymore Infrastructure Fund?
Fiduciary/Claymore Energy Infrastructure Fund is a closed ended equity mutual fund launched and managed by Guggenheim Funds Investment Advisors, LLC.
ebitda margin -hoz hasonló cégek Fiduciary/Claymore Infrastructure Fund
- Theralase Technologies nak EBITDA margin -476.04% van
- Sangamo Therapeutics Inc nak EBITDA margin -474.14% van
- Xinyang Maojian nak EBITDA margin -471.45% van
- WANdisco Plc nak EBITDA margin -470.42% van
- RYU Apparel nak EBITDA margin -468.27% van
- Barra Resources nak EBITDA margin -466.28% van
- Fiduciary/Claymore Infrastructure Fund nak EBITDA margin -466.20% van
- SRAX Inc nak EBITDA margin -465.79% van
- Xtract One Technolgies Inc nak EBITDA margin -464.36% van
- Spruce Biosciences nak EBITDA margin -462.16% van
- Sage Therapeutics Inc nak EBITDA margin -460.83% van
- Arcimoto Inc nak EBITDA margin -460.40% van
- Canopy Rivers nak EBITDA margin -458.36% van